Results of a Prospective Phase II Trial With Ofatumumab as Part of Reduced Intensity Conditioning Regimen in High-Risk Non-Hodgkin B Lymphoma Patients: A GELTAMO Trial

Hematological Oncology - United Kingdom

doi 10.1002/hon.2439_96